# Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
Canonical URL: https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2026-financial-results-and-operational-progress
Ticker: ATRA
Company: Atara Biotherapeutics, Inc.
Source: Atara Biotherapeutics, Inc.
Published: 2026-05-12 20:05 EST
Original Source URL: https://investors.atarabio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-12 20:05 EST — [Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2026-financial-results-and-operational-progress) — Source: Atara Biotherapeutics, Inc.
- 2026-03-16 20:05 EST — [Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-operational-progress) — Source: Atara Biotherapeutics, Inc.
- 2026-03-12 12:05 EST — [Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-regulatory-update-on-tabelecleucel) — Source: Atara Biotherapeutics, Inc.
- 2026-02-23 13:00 EST — [Atara Biotherapeutics Provides a Business Update](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-a-business-update) — Source: Atara Biotherapeutics, Inc.
- 2026-01-12 13:00 EST — [Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)](https://biopharmsignal.com/news/ATRA/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallotm-tabelecleucel) — Source: Atara Biotherapeutics, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)